(Q37848045)

24 August 2017

1 reference

title

Need for better diabetes treatment for improved renal outcome (English)

1 reference

24 August 2017

1

Peter Rossing

0 references

author name string

Dick de Zeeuw

series ordinal

2

1 reference

24 August 2017

1 March 2011

1 reference

Kidney International. Supplement

24 August 2017

1 reference

24 August 2017

120

1 reference

24 August 2017

S28-32

1 reference

Global estimates of the prevalence of diabetes for 2010 and 2030

24 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

The changing natural history of nephropathy in type I diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Declining incidence of persistent proteinuria in type I (insulin-dependent) diabetic patients in Denmark

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Declining Incidence of Nephropathy in Insulin-Dependent Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

The changing epidemiology of diabetic microangiopathy in type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Preventing microalbuminuria in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Effect of a multifactorial intervention on mortality in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

New drug targets for type 2 diabetes and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.513

7 January 2021

Identifiers

DOI

10.1038/KI.2010.513

1 reference

24 August 2017

1 reference

PubMed ID

21358699